cancer
Conditions
Interventions
blank control group:CIPN is treated with venlafaxine or duloxetine
experimental group:CIPN is treated with venlafaxine or duloxetine
Sponsors
The Second Affiliated Hospital of Fujian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Patients with peripheral neuropathy due to chemotherapy in the Second Affiliated Hospital of Fujian Medical University since December 2019 (1) male and female patients aged >=18 years old; (2) ECOG 0-1, survival time >3 months; (3) histologically confirmed as cancer, patients with Pretreatment sensory neuropathy grade of at least grade 1 or above on the NCI-CTCAE 5.0 neurotoxicity scale after chemotherapy; (4) patients older than 65 years and with diabetes mellitus were considered to be at high risk for neurotoxicity, and were stratified; (5) having full organ function, having the ability to swallow and retain oral medication.
Exclusion criteria
Exclusion criteria: (1) patients with tumors of the central nervous system or brain metastasis of cancer; (2) previous peripheral neuropathy of any degree except for chemotherapy; (3) previous use of antidepressants, anticonvulsants or other neuropathic analgesics; (4) the patient has an unstable psychological state; (5) a history of alcoholism; (6) for patients who are permitted to use a combination of selected analgesics (e.g., opioids, acetaminophen, aspirin, nsaids) in an unstable dose; (7) patients should be treated with monoamine oxidase inhibitors such as linezolid and intravenous methylene blue injection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in the total mean score of EORTC QLQ-CIPN20 questionnaire; | — |
Secondary
| Measure | Time frame |
|---|---|
| The magnitude change of NCI-CTCAE 5.0 CIPN;Changes in nerve conduction velocity;Incidence of adverse reactions; | — |
Countries
China
Contacts
Public ContactZhang Yin
The Second Affiliated Hospital of Fujian Medical University
Outcome results
None listed